B. Ceglarek

768 citations

15 papers · 425 indexed · h-index 9

Impact in

Genetics top 2%
- Chronic Lymphocytic Leukemia Research
Pathology and Forensic Medicine top 5%
- Lymphoma Diagnosis and Treatment

Papers in

Genetics 12
- Chronic Lymphocytic Leukemia Research 12
Pathology and Forensic Medicine 9
- Lymphoma Diagnosis and Treatment 9

Co-authors: Tadeusz Robak L Konopka Anna Dmoszyńska Andrzej Hellmann Jerzy Z. Błoński Jadwiga Dwilewicz‐Trojaczek Marek Kasznicki S Potoczek
Journals: Blood (7 papers)Cancer (1 paper)Journal of Clinical Oncology (1 paper)European Journal of Cancer (1 paper)Leukemia (1 paper)
Partner nations: Poland United States Thailand

In The Last Decade

B. Ceglarek

14 papers receiving 409 citations

Peers

Countries citing papers authored by B. Ceglarek

Since Specialization

Citations

This map shows the geographic impact of B. Ceglarek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B. Ceglarek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B. Ceglarek more than expected).

Fields of papers citing papers by B. Ceglarek

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by B. Ceglarek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B. Ceglarek. The network helps show where B. Ceglarek may publish in the future.

Co-authorship network

The 25 scholars most cited alongside B. Ceglarek, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with B. Ceglarek Line = papers co-authored together B. Ceglarek links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work
1	Clinical significance of slightly reduced von Willebrand factor activity (30–50 IU/dL) Polskie Archiwum Medycyny Wewnętrznej ·K. Bykowska, B. Ceglarek	2020	3
2	ST-Elevation Myocardial Infarction (STEMI) in a Patient with Antiphospholipid Syndrome (APS) secondary to Systemic Lupus Erythematosus (SLE) – a case report Acta Haematologica Polonica ·B. Ceglarek, A. Sikorska, K. Bykowska, Bülent Baran, Jerzy Windyga	2015	0
3	Comparison of Cladribine Plus Cyclophosphamide With Fludarabine Plus Cyclophosphamide As First-Line Therapy for Chronic Lymphocytic Leukemia: A Phase III Randomized Study by the Polish Adult Leukemia Group (PALG-CLL3 Study) Journal of Clinical Oncology ·Tadeusz Robak, Krzysztof Jamroziak, Joanna Góra‐Tybor, Beata Stella‐Hołowiecka, L Konopka, B. Ceglarek, Krzysztof Warzocha, Ilona Seferyńska, Jarosław Piszcz, Małgorzata Całbecka, Скворцова Валентина Алексеевна, Jadwiga Dwilewicz‐Trojaczek, Anna Dmoszyńska, Krystyna Zawilska, Andrzej Hellmann, S. Chen, S Potoczek, Magdalena Piotrowska, Krzysztof Lewandowski, Jerzy Z. Błoński	2010	71
4	Impact of Prior Therapy and Suboptimal Response to Imatinib On the Efficacy and Safety of Nilotinib Among 1,422 Patients with Imatinib-Resistant or —Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): Sub-Analyses of the ENACT (Expanding Nilotinib Access in Clinical Trials) Study. Blood ·Franck E. Nicolini, Dong‐Wook Kim, B. Ceglarek, Anna Turkina, Giuliana Alimena, Haifa Kathrin Al‐Ali, Zhixiang Shen, Saengsuree Jootar, Graeme Smith, Cármino Antônio De Souza, Pedro Enrique Dorlhiac‐Llacer, David A. Rizzieri, Tomasz Szczudlo, Yuanbing Song, Jim J. Wang, S Tazzyman, Philipp D. le Coutre	2009	10
5	Efficacy and Safety of Nilotinib in Elderly Patients with Imatinib-Resistant or -;Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): A Sub-Analysis of the ENACT (Expanding Nilotinib Access in Clinical Trials) Study. Blood ·Philipp D. le Coutre, Anna Turkina, Dong‐Wook Kim, B. Ceglarek, Giuliana Alimena, Haifa Kathrin Al‐Ali, Zhixiang Shen, Saengsuree Jootar, Graeme Smith, Cármino Antônio De Souza, Pedro Enrique Dorlhiac‐Llacer, David A. Rizzieri, Tomasz Szczudlo, Yuanbing Song, Jim J. Wang, Irniyazova Mavluda Shonazarovna, Franck E. Nicolini	2009	12
6	Patterns and Management of Selected Adverse Events of Adult Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) From the ENACT (Expanding Nilotinib Access in Clinical Trials) Study. Blood ·Philipp D. le Coutre, B. Ceglarek, Anna Turkina, Dong‐Wook Kim, Giuliana Alimena, Haifa Kathrin Al‐Ali, Zhixiang Shen, Saengsuree Jootar, Graeme Smith, Cármino Antônio De Souza, David A. Rizzieri, Tomasz Szczudlo, Yuanbing Song, Jim J. Wang, I Bulowski, Franck E. Nicolini	2009	9
7	Randomized comparison of cladribine alone or in combination with cyclophosphamide, and cyclophosphamide, vincristine and prednisone in previously untreated low‐grade B‐cell non‐Hodgkin lymphoma patients Cancer ·Ewa Kalinka‐Warzocha, Steven R. Earle, Ewa Lech‐Marańda, B. Ceglarek, Jerzy Hołowiecki, محمود بیات, Jan Walewski, Jarosław Czyż, Tadeusz Robak, Krzysztof Warzocha	2008	18
8	Randomized Comparison of Cladribine Single (C) or in Combination with Cyclophosphamide (CC), and COP in Previously Untreated Low Grade B-Cell Non-Hodgkin Lymphoma Patients. Blood ·Ewa Kalinka‐Warzocha, Steven R. Earle, K Sułek, Maria Błasińska-Morawiec, Rosfazliszah Zahit, B. Ceglarek, Tadeusz Robak, Jerzy Hołowiecki, Grzegorz Mazur, محمود بیات, Nikita Khetarpal, Marzena Wątek, Krzysztof Warzocha	2006	2
9	Comparison of cladribine plus prednisone with chlorambucil plus prednisone in patients with chronic lymphocytic leukemia. Final report of the Polish Adult Leukemia Group (PALG CLL1). PubMed ·Tadeusz Robak, Jerzy Z. Błoński, Marek Kasznicki, Joanna Góra‐Tybor, Anna Dmoszyńska, Risa Itoh, Aleksander B. Skotnicki, W. Nowak, Andrzej Hellmann, Krzysztof Lewandowski, Barbara Zdziarska, L Konopka, B. Ceglarek, Jadwiga Dwilewicz‐Trojaczek, Piotr Boguradzki, Kazimierz Kuliczkowski, K Sułek, Krzysztof Warzocha	2005	15
10	Randomized Multicenter Trial of Cladribine Alone (C) or in Combination with Cyclophosphamide (CC), and COP in Previously Untreated Low Grade B-Cell Non-Hodgkin Lymphoma Patients: The First Interim Analysis. Blood ·Kumar Pravat, Steven R. Earle, K Sułek, Tadeusz Robak, Maria Błasińska-Morawiec, Jerzy Hołowiecki, Nadjali A. Chung, B. Ceglarek, L Konopka, Grzegorz Mazur, محمود بیات, Luiz Belussi, Marzena Wątek, J.Widmer Rolph, J. Meder, Rosfazliszah Zahit, Ilona Seferyńska, Jarosław Czyż, Krzysztof Warzocha	2004	2
11	Cladribine Alone or in Combination with Cyclophosphamide or Cyclophosphamide and Mitoxantrone as First Line Treatment in Chronic Lymphocytic Leukemia: An Early Report of Prospective Randomized Study. Blood ·Tadeusz Robak, Jerzy Z. Błoński, Joanna Góra‐Tybor, Marek Kasznicki, Jadwiga Dwilewicz‐Trojaczek, Zhaojiu Han, L Konopka, B. Ceglarek, Janusz Kłoczko, M. Khouchan, Anna Dmoszyńska, Małgorzata Kowal, Krystyna Zawilska, Beata Stella‐Hołowiecka, K Sułek, Kazimierz Kuliczkowski, Krzysztof Warzocha, Małgorzata Całbecka, Aleksander B. Skotnicki	2004	8
12	Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukaemia treated with cladribine European Journal of Cancer ·Tadeusz Robak, Jerzy Z. Błoński, Joanna Góra‐Tybor, Marek Kasznicki, L Konopka, B. Ceglarek, Mieczysław Komarnicki, Krzysztof Lewandowski, Andrzej Hellmann, Sasivimon Rattanasiri, Anna Dmoszyńska, Sandra Alves, F Brosstad, Agnieszka Tomaszewska, K Sułek, Małgorzata Całbecka	2003	55
13	Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia Leukemia ·Tadeusz Robak, 김시욱, Marek Kasznicki, Joanna Góra‐Tybor, Jadwiga Dwilewicz‐Trojaczek, Piotr Boguradzki, L Konopka, B. Ceglarek, Jay Sulek, Kazimierz Kuliczkowski, Dariusz Wołowiec, Beata Stella‐Hołowiecka, A B Skotnicki, W. Nowak, Yangmei Du, Anna Dmoszyńska, Małgorzata Całbecka	2001	32
14	[Chronic eosinophilic leukemia]. PubMed ·Ulrike Hallaschka, Mara Mira Navarro, B. Ceglarek, A. Sikorska, David Roubaud, Charl Fregona, Sumit Kumar, L Konopka	2001	3
15	Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood ·Tadeusz Robak, Jerzy Z. Błoński, Marek Kasznicki, Maria Błasińska-Morawiec, E Krykowski, Anna Dmoszyńska, Edi Sulistyadi, Aleksander B. Skotnicki, W. Nowak, L Konopka, B. Ceglarek, S Maj, Jadwiga Dwilewicz‐Trojaczek, Andrzej Hellmann, I Urasiński, Barbara Zdziarska, S Kotlarek-Haus, S Potoczek, Paweł Grieb	2000	185

About B. Ceglarek

B. Ceglarek is a scholar working on Genetics, Pathology and Forensic Medicine, Hematology, Rheumatology and Public Health, Environmental and Occupational Health, having authored 15 papers that have together received 425 indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (12 papers), Lymphoma Diagnosis and Treatment (9 papers), Acute Lymphoblastic Leukemia research (5 papers), Immunodeficiency and Autoimmune Disorders (3 papers), Chronic Myeloid Leukemia Treatments (3 papers), Eosinophilic Disorders and Syndromes (2 papers), Advanced Breast Cancer Therapies (1 paper) and Viral Infections and Immunology Research (1 paper). The work is most often cited by research in Genetics (379 citations), Pathology and Forensic Medicine (305 citations), Hematology (95 citations), Immunology (145 citations) and Oncology (72 citations). B. Ceglarek has collaborated with scholars based in Poland, United States and Thailand. Frequent co-authors include Tadeusz Robak, L Konopka, Anna Dmoszyńska, Andrzej Hellmann, Jerzy Z. Błoński, Jadwiga Dwilewicz‐Trojaczek, Marek Kasznicki, S Potoczek, W. Nowak and Barbara Zdziarska. Their work appears in journals such as Blood, Cancer, Journal of Clinical Oncology, European Journal of Cancer and Leukemia.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact